Drug Information

Drug General Information
Drug ID
D0J5TN
Former ID
DNC000402
Drug Name
CEP-751
Drug Type
Small molecular drug
Indication Neurodegenerative disease [ICD9: 330-337; ICD10:G30-G32] Terminated [546524]
Structure
Download
2D MOL

3D MOL
Formula
C27H23N3O4
Canonical SMILES
CC12C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)<br />CNC6=O)(CO)OC
InChI
1S/C27H23N3O4/c1-26-27(13-31,33-2)11-19(34-26)29-17-9-5-3-7-14(17)21-22-16(12-28-25(22)32)20-15-8-4-6-10-18(15)30(26)24(20)23(21)29/h3-10,19,31H,11-13H2,1-2H3,(H,28,32)/t19?,26-,27-/m0/s1
InChIKey
NMMGUHANGUWNBN-OGLOGDKOSA-N
PubChem Compound ID
9868524
PubChem Substance ID
14833444, 24159857, 45290788, 79795288, 134339835
Target and Pathway
Target(s) Proto-oncogene tyrosine-protein kinase receptor ret Target Info Inhibitor [535832]
KEGG Pathway Endocytosis
Pathways in cancer
Thyroid cancer
Central carbon metabolism in cancer
Pathway Interaction Database Signaling events regulated by Ret tyrosine kinase
Posttranslational regulation of adherens junction stability and dissassembly
WikiPathways SIDS Susceptibility Pathways
Dopaminergic Neurogenesis
References
Ref 546524Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008742)
Ref 535832CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res. 2003 Sep 1;63(17):5559-63.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.